

1AP3 Rec'd PCT/PTO 24 FEB 2006  
PCT



PATENT  
Customer No. 22,852  
Attorney Docket No. 08201.0039-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
AMBROSE et al. ) Group Art Unit: 1647  
Application No.: 10/550,961 ) Examiner: Not Yet Assigned  
Filed: September 26, 2005 ) Confirmation No.: 1436  
For: TRUNCATED BAFF RECEPTORS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Applicant notes that WO 02/02641 is being submitted without Sequence Listing due to large size. Applicant is ready to provide Sequence Listing upon request. Copies of the U.S. patent publications are not enclosed.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: February 24, 2006

By:   
Konstantin M. Linnik  
Reg. No. 56,309

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	4	<b>Complete if Known</b>	
				Application Number	10/550,961
				Filing Date	September 26, 2005
				First Named Inventor	AMBROSE, Christine
				Art Unit	1647
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	08201.0039-00000

**U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		5,595,721	01/21/1997	Kaminski et al.	
		5,969,102	10/19/1999	Bram et al.	
		6,297,367	10/02/2001	Tribouley	
		6,316,222	11/13/2001	Bram et al.	
		6,403,770	06/11/2002	Yu et al.	
		6,475,986	11/05/2002	Aggarwal	
		6,475,987	11/05/2002	Shu	
		6,541,224	04/01/2003	Yu et al.	
		6,551,795	04/22/2003	Rubenfield et al.	
		6,623,941	09/23/2003	Ruben et al.	
		6,689,579	02/10/2004	Yu et al.	
		2002-0037852	03/28/2002	Browning et al.	
		2002-0165156	11/07/2002	Browning et al.	
		2002-0172674	11/21/2002	Browning et al.	
		2003-0023038	01/20/2003	Rennert et al.	
		2003-0082175	05/01/2003	Schneider et al.	
		2003-0092164	05/15/2003	Gross et al.	
		2003-0095967	05/22/2003	MacKay et al.	
		2003-0194743	10/16/2003	Beltzer et al.	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		WO 97/33902	09/18/1997	PCT		
		WO 98/18921	05/07/1998	PCT		
		WO 98/27114	06/25/1998	PCT		
		WO 98/39361	09/11/1998	PCT		
		WO 98/55621	12/10/1998	PCT		
		WO 98/55620	12/10/1998	PCT		
		WO 99/04001	01/28/1999	PCT		
		WO 99/11791	03/11/1999	PCT		
		WO 99/12964	03/18/1999	PCT		
		WO 99/12965	03/18/1999	PCT		

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	4	Attorney Docket Number	08201.0039-00000
-------	---	----	---	------------------------	------------------

**Complete if Known**

Application Number	10/550,961
Filing Date	September 26, 2005
First Named Inventor	AMBROSE, Christine
Art Unit	1647
Examiner Name	Not Yet Assigned

**FOREIGN PATENT DOCUMENTS**

	WO 99/33980	07/08/1999	PCT		
	WO 00/26244	05/11/2000	PCT		
	WO 00/39295	07/06/2000	PCT		
	WO 00/40716	07/13/2000	PCT		
	WO 00/43032	07/27/2000	PCT		
	WO 00/50597	08/31/2000	PCT		
	WO 00/50633	08/31/2000	PCT		
	WO 00/58362	10/05/2000	PCT		
	WO 01/12812	02/22/2001	PCT		
	WO 01/24811	04/12/01	PCT		
	WO 02/02641	01/10/2002	PCT		
	WO 02/18620	03/07/2002	PCT		
	WO 02/024909	03/28/2002	PCT		
	WO 02/092620	11/21/2002	PCT		
	WO 02/38766	05/16/2002	PCT		
	WO 03/014294	02/20/2003	PCT		
	WO 03/024991	03/27/2003	PCT		
	WO 03/035846	05/01/2003	PCT		
	WO 03/055979	07/10/2003	PCT		
	WO 04/035735	04/29/2004	PCT		
	WO 05/005462	01/20/2005	PCT		
	EP 0 869 180 A1	10/07/1998	EPC		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		Database Accession No. AI250289, XP002206618	
		Database Accession No. Z99716.4, XP002206619	
		Do et al., "Attenuation of apoptosis underlies B Lymphocyte stimulator enhancement of humoral immune response," <i>J. Exp. Med.</i> 192(7):953-964 (2000)	
		Domingues, H.M., "Rational design strategies to improve cytokine foldability and minimization of a functional motif: The IL-4 Case," <i>Thesis University of Utrecht</i> , p. 48, line 25 – p. 51, line 6, page 94; table III (1999)	
		GenBank Accession No. AK008142, Published February 16, 2001	
		Gordon et al., "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site," <i>Biochemistry</i> 42:5977-5983 (2003)	
		Gras et al., "BCMAp: An integral membrane protein in the Golgi apparatus of human mature B lymphocytes," <i>Int. Immunology</i> 7(7):1093-1106 (1995)	
		Gross et al., "TACI and BCMA are receptors for a TNF homologue implicated in B-Cell autoimmune disease," <i>Nature</i> , 404:995-999 (2000)	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	3	of	4	Attorney Docket Number
				08201.0039-00000

**FOREIGN PATENT DOCUMENTS**

	Hahne et al., "APRIL, a new ligand of the tumor necrosis family, stimulates tumor cell growth," <i>J. Exp. Med.</i> 188(6):1185-1190 (1998)	
--	---	--

	Kashii, Y. et al., "Constitutive expression and role of the family ligands in apoptotic killing of tumor cells by human NK cells," <i>J. Immunol.</i> 163:5358-66 (1999)	
	Kayagaki et al. "BAFF/BLyS receptor 3 binds the B Cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF- $\kappa$ B2," <i>Immunity</i> 10:515-524 (2002)	
	Khare et al., "The role of TALL-1 and APRIL in immune regulations," <i>Trends Immunol.</i> 22(2):61-63 (2001)	
	Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>PNAS</i> 97(7):3370-3375 (2000)	
	Kwon et al., "Single amino acid substitutions of $\alpha_1$ -Antitrypsin that confer enhancement in thermal stability," <i>J. Biol. Chem.</i> , 269:9627-9631 (1994)	
	Laabi et al., "A BCMA gene, preferentially expressed during B lymphoid maturation, 13 bidirectionally transcribed," <i>Nucleic Acids Res.</i> 22(7):1147-1154 (1994)	
	Laabi et al., "The new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26,p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> 11:3897-3904 (1992)	
	Mackay et al., "Mice transgenic for BAFF develop lymphocyte disorders along with autoimmune manifestations," <i>J. Exp. Med.</i> 190(11):1697-1710 (1999)	
	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," <i>Int. Immunol.</i> 10(11):1693-1702 (1998)	
	Marsters et al., "Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Curr. Biol.</i> , 10:785-788 (2000)	
	Moore et al., "BlyS, Member of the tumor necrosis factor family and B lymphocyte stimulator," <i>Science</i> 282:260-263 (1999)	
	Schein, C.H., "Production of soluble recombinant proteins in bacteria," <i>Biotechnology</i> , 7:1141-1149 (1989)	
	Schiemann et al., "An essential role for BAFF in the normal development of B Cells through a BCMA-independent pathway," <i>Science</i> , 293:2111-2114 (2001)	
	Schneider et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth," <i>J. Exp. Med.</i> , 189:1747-1756 (1999)	
	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-683 (1999)	
	Thompson et al., "BAFF binds to the tumor necrosis factor receptor-like molecule B Cell maturation antigen and is important for maintaining the peripheral B Cell population," <i>J. Exp. Med.</i> , 192:129-135 (2000)	
	Thompson et al., "BAFF-R, a newly identified TNF Receptor that specifically interacts with BAFF," <i>Science</i> , 293:2108-2111 (2001)	
	von Bulow & Bram, "NT-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily," <i>Science</i> 278:138-141 (1997)	
	Waldschmidt et al., "Long Live the Mature B-Cell – A baffling mystery resolved," <i>Science</i> , 293:2012-2013 (2001)	
	Ward, P. and Mulligan, M. "Blocking of adhesion molecules <i>in vivo</i> as anti-inflammatory therapy," <i>Ther. Immunol.</i> 1:165-71 (1994)	
	Ware, C., "April and BAFF connect autoimmunity and cancer," <i>J. Exp. Med.</i> 192:F35-F37 (2000)	
	Wood et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide $\beta$ /A4," <i>Biochemistry</i> , 34:724-730 (1995)	
	Wu et al., "Tumor Necrosis Factor (TNF) receptor superfamily member TACI is a high affinity receptor of TNF family members APRIL and BlyS," <i>J. Biol. Chem.</i> 275(45):35478-35485 (2000)	
	Yan et al., "Identification of a novel receptor for B Lymphocyte stimulator that is mutated in a mouse strain with severe B Cell deficiency," <i>Curr. Biol.</i> , 11:1547-1552 (2001)	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

<i>Application Number</i>	10/550,961
<i>Filing Date</i>	September 26, 2005
<i>First Named Inventor</i>	AMBROSE, Christine
<i>Art Unit</i>	1647
<i>Examiner Name</i>	Not Yet Assigned
<i>Attorney Docket Number</i>	08201.0039-00000

		Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: System for regulating humoral immunity," <i>Nature Immunology</i> , 1:252-256 (2000)	
--	--	--	--